Diane Wang on Muck Rack

Diane Wang

As seen in: LinkedIn, MSN, Forbes, Nature, Wiley Online Library, Entrepreneur, Entrepreneur en Español, South China Morning Post, JAMA (The Journal of the American Medical Association), Science Magazine and
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Diane

Contact Diane, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Limitations of Subgroup Safety Analyses for Drug–Drug Interaction Evaluation: Insights from the Talazoparib P-gp Inhibitor Case

|
By Diane Wang, Charvi Nanavati, Derek Z. Yang PharmD
| Wiley Online Library
Introduction Characterizing clinically relevant drug–drug interactions (DDIs) is an important aspect of drug development. The focus of DDI evaluation lies in assessing the extent of changes in drug exposure, which are examined within the context of the exposure-response (ER) relationship for safety and/or efficacy to recommend adequate management strategies upon coadministration (e.g., dose adjustments).
Open in Who Shared Issue with article?

Elranatamab Exposure-Safety Analysis in Relapsed or Refractory Multiple Myeloma

|
By Pooneh Soltantabar, Jennifer E. Hibma, Diane Wang, Umberto Conte
| Wiley Online Library
Introduction Multiple myeloma (MM) is a hematologic malignancy characterized by the clonal proliferation of transformed plasma cells.1 In 2024, MM was anticipated to represent 19% of all hematologic malignancies and 1.8% of all cancers in the United States, according to American Cancer Society estimates.2 Despite significant strides in MM treatment, a definitive cure remains elusive for most patients.
Open in Who Shared Issue with article?

Talazoparib Formulation Bridging in Cancer Patients-Challenges and the Critical Role of Model‐Informed Drug Development in Approval Despite Failed Bioequivalence - Wang - CPT: Pharmacometrics & Systems Pharmacology - Wiley Online Library

|
By Diane Wang, Xizhe Gao, Yibo Wang, Cathy Cen Guo
| Wiley Online Library
What is the current knowledge on the topic? ○ After the initial approval of talazoparib, a new soft gelatin capsule (SGC) formulation was developed and bridging with the initial commercial hard capsule (HC) formulation was needed. For post-approval formulation bridging, the demonstration of both AUC and Cmax equivalence in a bioequivalence (BE) study and evaluation of food effect (FE) are generally required.
Open in Who Shared Issue with article?
See all 36 articles

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Get in touch with Diane

Contact Diane, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack
 •  Privacy  •  Terms  •  Security and Legal  •   •   •   • 

© 2026 Muck Rack

SOC 2® Certified